{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:41:50Z","timestamp":1782405710343,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Belantamab mafodotin (belamaf) has demonstrated clinically meaningful antimyeloma activity in patients with heavily pretreated multiple myeloma. However, it is highly active against dividing cells, contributing to off-target adverse events, particularly ocular toxicity. Changes in best corrected visual acuity (BCVA) and corneal examination findings are routinely monitored to determine Keratopathy Visual Acuity (KVA) grade to inform belamaf dose modification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to develop a semiautomated mobile app to facilitate the grading of ocular events in clinical trials involving belamaf.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The paper process was semiautomated by creating a library of finite-state automaton (FSA) models to represent all permutations of KVA grade changes from baseline BCVA readings. The transition states in the FSA models operated independently of eye measurement units (e.g., Snellen, logMAR, decimal) and provided a uniform approach to determining KVA grade changes. Together with the FSA, the complex decision tree for determining the grade change based on corneal examination findings was converted into logical statements for accurate and efficient overall KVA grade computation. First, a web-based user interface, conforming to clinical practice settings, was developed to simplify the input of key KVA grading criteria. Subsequently, a mobile app was developed that included additional guided steps to assist in clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The app underwent a robust Good Clinical Practice validation process. Outcomes were reviewed by key stakeholders, our belamaf medical lead, and the systems integration team. The time to compute a patient's overall KVA grade using the Belamaf Eye Exam (BEE) app was reduced from a 20- to 30-min process to &amp;lt;1\u20132\u2005min. The BEE app was well received, with most investigators surveyed selecting \u201csatisfied\u201d or \u201chighly satisfied\u201d for its accuracy and time efficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our semiautomated approach provides for an accurate, simplified method of assessment of patients\u2019 corneal status that reduces errors and quickly delivers information critical for potential belamaf dose modifications. The app is currently available on the Apple iOS and Android platforms for use by investigators of the DREAMM clinical trials, and its use could easily be extended to the clinic to support healthcare providers who need to make informed belamaf treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fdgth.2023.1138453","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:16:06Z","timestamp":1696922166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Semi-automation of keratopathy visual acuity grading of corneal events in belantamab mafodotin clinical trials: clinical decision support software"],"prefix":"10.3389","volume":"5","author":[{"given":"Mala K.","family":"Talekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery L.","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mica A.","family":"Elizalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather K.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relpased\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relpased\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/s1470-2045(18)30576-x","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/s1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the international myeloma working group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"678634","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2040620721989585","DOI":"10.1177\/2040620721989585","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.ajoc.2021.101133","article-title":"Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography","volume":"23","author":"Matsumiya","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B11","volume-title":"Introduction to automata theory, languages, and computation","author":"Hopcroft","year":"2000"},{"key":"B12","first-page":"5883","article-title":"Using JSON for data exchanging web service applications","volume":"7","author":"Peng","year":"2011","journal-title":"J Comput Inf Syst"},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1145\/364955.364989","article-title":"Conversion of decision tables to computer programs","volume":"8","author":"Press","year":"1965","journal-title":"Commun ACM"},{"key":"B14","volume-title":"Envisioning information, vol. 126","author":"Tufte","year":"1990"},{"key":"B15","year":"2018"},{"key":"B16","year":"2014"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/S2152-2650(21)02329-6","article-title":"P-202: characteriziation of ocular adverse events in patients receiving belantamab mafadotin for \u226512 months: post-hoc analysis of DREAMM-2 study in relpased\/refractory multiple myeloma","volume":"21","author":"Lonial","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2023.1138453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:16:10Z","timestamp":1696922170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2023.1138453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":17,"alternative-id":["10.3389\/fdgth.2023.1138453"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2023.1138453","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"article-number":"1138453"}}